Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells

Bioconjugate Chemistry

Volumn 22, Issue 12, 2011, Pages 2474-2486

  Ernsting, Mark J ^a   Tang, Wei Lun ^a   Maccallum, Noah ^a   Li, Shyh Dar ^a  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLATION; CARBOXYLATION; CELL CULTURE; CELLS; CONTROLLED DRUG DELIVERY; DISEASES; DRUG PRODUCTS; NANOPARTICLES; ORGANIC SOLVENTS; TARGETED DRUG DELIVERY;

'CURRENT; CANCER CELLS; CARBOXYMETHYL CELLULOSE; DELIVERY SYSTEMS; DOCETAXEL; NANOPARTICLE FORMULATION; PEGYLATION; SLOW RELEASE; SYNTHETIC MODIFICATIONS; TAXANES;

POLYETHYLENE GLYCOLS;

CARBOXYMETHYLCELLULOSE; DOCETAXEL; EXCIPIENT; MACROGOL; NANOPARTICLE;

ACETYLATION; ANIMAL CELL; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

MURINAE;

EID: 83355162188     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200284b     Document Type: Article

References (86)

1. Singla, A. K., Garg, A., and Aggarwal, D. (2002) Paclitaxel and its formulations Int. J. Pharm. 235, 179-92 (Pubitemid 34185449)
2. Shelley, W. B., Talanin, N., and Shelley, E. D. (1995) Polysorbate 80 hypersensitivity Lancet 345, 1312-3
3. Gelderblom, H., Verweij, J., Nooter, K., and Sparreboom, A. (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37, 1590-8 (Pubitemid 32778603)
4. Jones, S. (2006) Head-to-head: Docetaxel challenges paclitaxel EJC Suppl. 4, 4-8
5. Etrych, T., Sirova, M., Starovoytova, L., Rihova, B., and Ulbrich, K. (2010) HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release Mol. Pharm. 7, 1015-26
6. Liu, J., Zahedi, P., Zeng, F., and Allen, C. (2008) Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel J. Pharm. Sci. 97, 3274-90
7. Esmaeili, F., Dinarvand, R., Ghahremani, M. H., Amini, M., Rouhani, H., Sepehri, N., Ostad, S. N., and Atyabi, F. (2009) Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies J. Pharm. Sci. 98, 2718-30
8. Li, C. and Wallace, S. (2008) Polymer-drug conjugates: recent development in clinical oncology Adv. Drug Delivery Rev. 60, 886-98
9. Duncan, R. (2003) The dawning era of polymer therapeutics Nat. Rev. Drug Discovery 2, 347-60 (Pubitemid 37361705)
10. Ringsdorf, H. (1975) Structure and properties of pharmacologically active polymers J. Polym. Sci., Polym. Symp. 51, 135-153
11. Yamaoka, T., Tabata, Y., and Ikada, Y. (1994) Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice J. Pharm. Sci. 83, 601-6 (Pubitemid 24222392)
12. Seymour, L. W., Duncan, R., Strohalm, J., and Kopecek, J. (1987) Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats J. Biomed. Mater. Res. 21, 1341-58
13. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanisms of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46, 6387-6392 (Pubitemid 17221789)
14. Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., and McDonald, D. M. (2000) Openings between defective endothelial cells explain tumor vessel leakiness Am. J. Pathol. 156, 1363-80 (Pubitemid 30660013)
15. Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., and Jain, R. K. (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc. Natl. Acad. Sci. U. S. A. 95, 4607-12 (Pubitemid 28207960)
16. Greish, K. (2010) Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting Methods Mol. Biol. 624, 25-37
17. Greish, K. (2007) Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines J. Drug Targeting 15, 457-64 (Pubitemid 47209047)
18. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., and Jain, R. K. (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55, 3752-6
19. Gabizon, A., Shmeeda, H., and Barenholz, Y. (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42, 419-36 (Pubitemid 36649037)
20. Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W., and Kirpotin, D. B. (2008) Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development J. Pharm. Sci. 97, 4696-740
21. Lindner, L. H. and Hossann, M. (2010) Factors affecting drug release from liposomes Curr. Opin. Drug Discovery Dev. 13, 111-23
22. Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., Shimada, Y., Nakahama, H., and Matsumura, Y. (2007) A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation Br. J. Cancer 97, 170-6 (Pubitemid 47057476)
23. Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., and Kakizoe, T. (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel Br. J. Cancer 92, 1240-6 (Pubitemid 40604398)
24. Lavasanifar, A., Samuel, J., and Kwon, G. S. (2002) Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery Adv. Drug Delivery Rev. 54, 169-90 (Pubitemid 34230440)
25. Ahmed, F., Pakunlu, R. I., Brannan, A., Bates, F., Minko, T., and Discher, D. E. (2006) Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug J. Controlled Release 116, 150-8 (Pubitemid 44868999)
26. Discher, D. E. and Ahmed, F. (2006) Polymersomes Annu. Rev. Biomed. Eng. 8, 323-41 (Pubitemid 44314820)
27. Katz, J. S., Levine, D. H., Davis, K. P., Bates, F. S., Hammer, D. A., and Burdick, J. A. (2009) Membrane stabilization of biodegradable polymersomes Langmuir 25, 4429-34
28. Svenson, S. and Tomalia, D. A. (2005) Dendrimers in biomedical applications - reflections on the field Adv. Drug Delivery Rev. 57, 2106-29 (Pubitemid 41759389)
29. Tekade, R. K., Kumar, P. V., and Jain, N. K. (2009) Dendrimers in oncology: an expanding horizon Chem. Rev. 109, 49-87
30. Tomalia, D. A., Reyna, L. A., and Svenson, S. (2007) Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging Biochem. Soc. Trans. 35, 61-7
31. Misra, R., Acharya, S., and Sahoo, S. K. (2010) Cancer nanotechnology: application of nanotechnology in cancer therapy Drug Discovery Today 15, 842-50
32. Li, S. D. and Huang, L. (2008) Pharmacokinetics and biodistribution of nanoparticles Mol. Pharmaceutics 5, 496-504
33. Harris, J. M. and Zalipsky, S., American Chemical Society, Division of Polymer Chemistry, and American Chemical Society, Meeting (1997) Poly(ethylene glycol): chemistry and biological applications, American Chemical Society, Washington, DC.
34. Immordino, M. L., Dosio, F., and Cattel, L. (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomed. 1, 297-315
35. Owens, D. E., 3rd and Peppas, N. A. (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307, 93-102 (Pubitemid 41773257)
36. Harris, J. M., Martin, N. E., and Modi, M. (2001) Pegylation: a novel process for modifying pharmacokinetics Clin. Pharmacokinet. 40, 539-51 (Pubitemid 32738660)
37. Lim, W. T., Tan, E. H., Toh, C. K., Hee, S. W., Leong, S. S., Ang, P. C., Wong, N. S., and Chowbay, B. (2010) Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors Ann. Oncol. 21, 382-8
38. Boddy, A. V., Plummer, E. R., Todd, R., Sludden, J., Griffin, M., Robson, L., Cassidy, J., Bissett, D., Bernareggi, A., Verrill, M. W., and Calvert, A. H. (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules Clin. Cancer Res. 11, 7834-40 (Pubitemid 41611628)
39. Letchford, K., Liggins, R., Wasan, K. M., and Burt, H. (2009) In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles Eur. J. Pharm. Biopharm. 71, 196-206
40. Li, C., Yu, D. F., Newman, R. A., Cabral, F., Stephens, L. C., Hunter, N., Milas, L., and Wallace, S. (1998) Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate Cancer Res. 58, 2404-9 (Pubitemid 28252701)
41. Duncan, R. (2006) Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6, 688-701 (Pubitemid 44286001)
42. Li, C. (2002) Poly(L-glutamic acid) - anticancer drug conjugates Adv. Drug Delivery Rev. 54, 695-713 (Pubitemid 35247523)
43. Li, C., Newman, R. A., Wu, Q. P., Ke, S., Chen, W., Hutto, T., Kan, Z., Brannan, M. D., Charnsangavej, C., and Wallace, S. (2000) Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor Cancer Chemother. Pharmacol. 46, 416-22
44. Turaev, A. S. (1995) Dependance of the biodegradability of carboxymethylcellulose on its supermolecular structure and molecular parameters Chem. Nat. Compd. 31, 254-257
45. Liu, Z., Jiao, Y., Wang, Y., Zhou, C., and Zhang, Z. (2008) Polysaccharides-based nanoparticles as drug delivery systems Adv. Drug Delivery Rev. 60, 1650-62
46. Janes, K. A., Calvo, P., and Alonso, M. J. (2001) Polysaccharide colloidal particles as delivery systems for macromolecules Adv. Drug Delivery Rev. 47, 83-97 (Pubitemid 32209234)
47. Prabaharan, M. (2008) Review paper: chitosan derivatives as promising materials for controlled drug delivery J. Biomater. Appl. 23, 5-36
48. Prabaharan, M. and Mano, J. F. (2005) Chitosan-based particles as controlled drug delivery systems Drug Delivery 12, 41-57 (Pubitemid 40066260)
49. Cera, C., Palumbo, M., Stefanelli, S., Rassu, M., and Palu, G. (1992) Water-soluble polysaccharide-anthracycline conjugates: biological activity Anti-Cancer Drug Des. 7, 143-51
50. Uglea, C. V., Parv, A., Corjan, M., Dumitriu, A. D., and Ottenbrite, R. M. (2005) Biodistribution and antitumor activity induced by carboxymethylcellulose conjugates J. Bioact. Compat. Polym. 20, 571-583 (Pubitemid 41641327)
51. Auzenne, E., Ghosh, S. C., Khodadadian, M., Rivera, B., Farquhar, D., Price, R. E., Ravoori, M., Kundra, V., Freedman, R. S., and Klostergaard, J. (2007) Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts Neoplasia 9, 479-86 (Pubitemid 46983450)
52. Inoue, K., Kumazawa, E., Kuga, H., Susaki, H., Masubuchi, N., and Kajimura, T. (2003) CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data Adv. Exp. Med. Biol. 519, 145-53 (Pubitemid 36577705)
53. Soepenberg, O., de Jonge, M. J., Sparreboom, A., de Bruin, P., Eskens, F. A., de Heus, G., Wanders, J., Cheverton, P., Ducharme, M. P., and Verweij, J. (2005) Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors Clin. Cancer Res. 11, 703-11 (Pubitemid 40116898)
54. Wang, X., Li, J., Wang, Y., Cho, K. J., Kim, G., Gjyrezi, A., Koenig, L., Giannakakou, P., Shin, H. J., Tighiouart, M., Nie, S., Chen, Z. G., and Shin, D. M. (2009) HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors ACS Nano 3, 3165-74
55. Sugahara, S., Kajiki, M., Kuriyama, H., and Kobayashi, T. R. (2007) Complete regression of xenografted human carcinomas by a paclitaxel- carboxymethyl dextran conjugate (AZ10992) J. Controlled Release 117, 40-50 (Pubitemid 46161869)
56. Hou, W., Watters, J. W., and McLeod, H. L. (2004) Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 804, 263-7 (Pubitemid 38481700)
57. Kumar, D., Tomar, R. S., Deolia, S. K., Mitra, M., Mukherjee, R., and Burman, A. C. (2007) Isolation and characterization of degradation impurities in docetaxel drug substance and its formulation J. Pharm. Biomed. Anal. 43, 1228-35
58. Kerns, E. H., Volk, K. J., Hill, S. E., and Lee, M. S. (1994) Profiling taxanes in Taxus extracts using lc/ms and lc/ms/ms techniques J. Nat. Prod. 57, 1391-403 (Pubitemid 24369955)
59. Namikoshi, H. (1985) Carboxyalkyl acetyl celluloses, their salts and a process for the preparation of them, U. S. Patent 4520192.
60. Zhang, X., Jackson, J. K., and Burt, H. M. (1996) Determination of surfactant critical micelle concentration by a novel fluorescence depolarization technique J. Biochem. Biophys. Methods 31, 145-50 (Pubitemid 26059157)
61. Miele, E., Spinelli, G. P., Tomao, F., and Tomao, S. (2009) Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer Int. J. Nanomed. 4, 99-105
62. Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., and Desai, N. (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin. Cancer Res. 11, 4136-43 (Pubitemid 40791578)
63. Duncan, R. and Vicent, M. J. (2010) Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities Adv. Drug Delivery Rev. 62, 272-82
64. Shaffer, S. A., Baker-Lee, C., Kennedy, J., Lai, M. S., de Vries, P., Buhler, K., and Singer, J. W. (2007) In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases Cancer Chemother. Pharmacol. 59, 537-48 (Pubitemid 46122332)
65. Charpentier, D., Mocanu, G., Carpov, A., Chapelle, S., Merle, L., and Muller, G. (1997) New hydrophobically modified carboxymethylcellulose derivitives Carbohydr. Polym. 33, 177-186 (Pubitemid 127395267)
66. Facchini, A. and Segatti, F. (2005) N-methyl-amine derivitives of Carboxymethylcellulose, alginic acid N-methyl-amide or carboxymethyl starch, Eur. Patent EP 1 614 696 A1.
67. Bilati, U., Allemann, E., and Doelker, E. (2005) Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles Eur. J. Pharm. Sci. 24, 67-75 (Pubitemid 40051288)
68. Lee, H., Lee, K., and Park, T. G. (2008) Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity Bioconjugate Chem. 19, 1319-25 (Pubitemid 351874956)
69. Van, S., Das, S. K., Wang, X., Feng, Z., Jin, Y., Hou, Z., Chen, F., Pham, A., Jiang, N., Howell, S. B., and Yu, L. (2010) Synthesis, characterization, and biological evaluation of poly(L-gamma-glutamyl-glutamine)- paclitaxel nanoconjugate Int. J. Nanomed. 5, 825-37
70. Fairley, N., Hoang, B., and Allen, C. (2008) Morphological control of poly(ethylene glycol)-block-poly(epsilon-caprolactone) copolymer aggregates in aqueous solution Biomacromolecules 9, 2283-91
71. Zhao, C. L., Winnik, M. A., Riess, G., and Croucher, M. D. (1990) Fluorescence probe technique used to study micelle formation in water soluble block copolymers Langmuir 6, 514-516 (Pubitemid 20663816)
72. Trivedi, R. and Kompella, U. B. (2010) Nanomicellar formulations for sustained drug delivery: strategies and underlying principles Nanomedicine (Lond.) 5, 485-505
73. Liggins, R. T. and Burt, H. M. (2002) Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations Adv. Drug Delivery Rev. 54, 191-202 (Pubitemid 34230441)
74. Luo, J., Xiao, K., Li, Y., Lee, J. S., Shi, L., Tan, Y. H., Xing, L., Holland Cheng, R., Liu, G. Y., and Lam, K. S. (2010) Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment Bioconjugate Chem. 21, 1216-24
75. Fanzioni, S., Hovda, K., Livi, V., KcKennon, M., Siviero, L., and Spoonemore, H. (2010) Method for determining the amount of conjugated taxane in polyglut acid-taxane conjugates, U. S. Patent 2010/0151582 A1.
76. Kerns, E. H., Volk, K. J., and Hill, S. E. (1995) Profiling new taxanes using LC/MS and LC/MS/MS substructural analysis techniques Rapid Commun. Mass Spectrom. 9, 1539-1545
77. Vuilhorgne, M., Gaillard, C., Sanderink, G., Royer, I., Monsarrat, B., Dubois, J., and Wright, M. (1994) Metabolism of Taxoid Drugs, ACS Symposium Series, Vol. 583, American Chemical Society, Washington, DC.
78. Bournique, B. and Lemarie, A. (2002) Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme Drug Metab. Dispos. 30, 1149-52 (Pubitemid 35265818)
79. Wang, X., Zhao, G., Van, S., Jiang, N., Yu, L., Vera, D., and Howell, S. B. (2010) Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts Cancer Chemother. Pharmacol. 65, 515-26
80. Liu, B., Yang, M., Li, R., Ding, Y., Qian, X., Yu, L., and Jiang, X. (2008) The antitumor effect of novel docetaxel-loaded thermosensitive micelles Eur. J. Pharm. Biopharm. 69, 527-34
81. EU. ((2010) European Medicines Agency-Assessment Report: Docefrez
82. Khandare, J. J., Jayant, S., Singh, A., Chandna, P., Wang, Y., Vorsa, N., and Minko, T. (2006) Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel Bioconjugate Chem. 17, 1464-72 (Pubitemid 44851491)
83. Yvon, A. M., Wadsworth, P., and Jordan, M. A. (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells Mol. Biol. Cell 10, 947-59 (Pubitemid 29193723)
84. De Souza, R., Zahedi, P., Mariyama, C., H., Allen, C., Wilson, B. C., and Paquette-Miller, M. (2010) Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer Mol. Cancer Therapeut. 9, 1820-1830
85. Lord, R., Nair, S., Schache, A., Spicer, J., Somaihah, N., Khoo, V., and Pandha, H. (2007) Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study J. Urol. 177, 2136-40 (Pubitemid 46726410)
86. Kamat, A. A., Kim, T. J., Landen, C. N., Jr., Lu, C., Han, L. Y., Lin, Y. G., Merritt, W. M., Thaker, P. H., Gershenson, D. M., Bischoff, F. Z., Heymach, J. V., Jaffe, R. B., Coleman, R. L., and Sood, A. K. (2007) Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer Cancer Res. 67, 281-8 (Pubitemid 46142786)